Bridged piperidine derivatives

US10899766B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Bjoern Bartels · Schopfheim, DE
• Roland Jakob-Roetne · Inzlingen, DE
• Anja Limberg · Penzberg, DE
• Werner Neidhart · Hagenthal-le-Bas, FR
• Hasane Ratni · Habsheim, FR
• Michael Reutlinger · Glückstadt, DE
• Jérôme Charles Sarie · Basel, CH
• Greta Vastakaite · Basel, CH

Key dates

• Filing date: Sep 28, 2017
• Grant date: Jan 26, 2021
• Expiry date: Sep 28, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound of formula (I), wherein R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy or lower alkoxy substituted by halogen; R may be the same or different, if n=2 or 3; n is 1, 2 or 3; m is 1, 2 or 3; Ar is a five or six membered heteroaryl group, selected from (II), (III), (IV) or (V) wherein R2 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen or lower alkoxy; R3 is hydrogen or halogen; -( ) m-is —(CH2)m— or to pharmaceutically active acid addition salts thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-in-farct dementia, dementia pugilistica or Down syndrome.